Surmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3
- Tesla lifts Nasdaq to record high
- Bitcoin (BTC) Recovers to $34,000 as Analysts Insists Crypto Winter Won't Repeat Again
- Dollar slips after Fed's Powell downplays inflation fears
- Cathie Wood's ARK Buys ~$77M in Bitcoin-Related Securities Yesterday on Dip
- Microsoft (MSFT) Price Target Raised to 'Street High' $325 at Wedbush as Cloud Story Is Not Slowing Down
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Webcast is Live at 7:30 a.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2017 conference call on Thursday, August 3, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will recap the third quarter 2017 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Company’s website at www.surmodics.com the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 10:30 a.m. CT on Thursday, August 3, until 10:30 a.m. CT on Thursday, August 10, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 3371788. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total product solutions, Surmodics’ mission remains to improve the detection and treatment of disease by using its technology to provide solutions to difficult medical device and diagnostic challenges. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Andy LaFrence, 952-500-7000
Source: Surmodics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Focus Financial Partners Inc. (FOCS) Launches Secondary Offering of 7.4M Shares
- Entera Bio Ltd. (ENTX) Phase 2 BMD for EB613 Study Met Its Primary and Key Secondary Endpoints
- GameStop (GME) Completes At-The-Market Equity Offering Program, Raising $1.126B
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!